Interview with Anna Gajec, General Manager, Cegedim Poland
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
Address: Al. Jerozolimskie 136
02-305 Warszawa
Al. Jerozolimskie 136
02-305 Warszawa
Al. Jerozolimskie 136
02-305 Warszawa
Al. Jerozolimskie 136 – 02-305 Warszawa, Poland
Tel: +48 22 389 1000
Web: http://www.cegedim.com/Pages/default.aspx
Cegedim Relationship Management helps its Life Sciences clients strengthen their customer relationships, enhance sales effectiveness, optimize data quality, improve marketing performance, and mitigate regulatory compliance risks. With a presence in more than 80 countries, Cegedim Relationship Management combines its global expertise with a deep understanding of local markets to help clients promote and market their products in the most efficient and cost-effective manner.
Leveraging our industry experience with specialized insight into commercial models and federal and state regulations, Cegedim Relationship Management offers companies of all sizes a targeted approach to optimizing growth within the evolving Life Sciences industry.
Cegedim Relationship Management provides commercial, regulatory compliance and data optimization solutions for the Life Sciences industry, enabling targeted solutions for strengthened client customer relationships, enhanced sales effectiveness, improved marketing performance and mitigated regulatory compliance risks.
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
Poland has an important manufacturing role for the CEE region and this is where Mylan has settled Agila, a state-of-the-art, high quality injectables manufacturing platform. Mylan has great ambitions in…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Sanofi’s General Manager in Poland, Marynika Woroszylska-Sapieha, shares two very important concepts that showcase the situation in Poland, stating that: “The biggest obstacle to innovation in Poland is the threshold…
“Average pharmaceutical company expenditures on R&D are in the range of 13 to 15 percent of revenues: much higher than the global average, and much higher than other Polish industrial…
“The swelling influence of wholesalers in the market frightens me.” With three wholesalers in Poland holding 80 percent of the market and establishing their own brands in a changing environment,…
“Instead of creating a state pharmaceutical duopoly, we have created an environment where the pharma industry can introduce new products and market them enthusiastically. This creates a market where pharmaceutical…
Persistence is a blessing, explains Glenmark’s Country Manager for Poland, Andrzej Gondek. By adapting a new product strategy to increase their OTC portfolio, Glenmark managed to nearly double its sales…
See our Cookie Privacy Policy Here